BIOA Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

24.930

Open

24.880

VWAP

24.24

Vol

518.34K

Mkt Cap

1.08B

Low

23.385

Amount

12.56M

EV/EBITDA(TTM)

Total Shares

44.45M

722.17M

EV/OCF(TTM)

P/S(TTM)

90.51

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

Events Timeline

(ET)

2026-06-16

08:30:00

BioAge Labs Doses First Participant in QUELL-CV Trial

2026-05-08 (ET)

2026-05-08

09:10:00

BioAge Reports Q1 Revenue of $2.77M, Exceeding Expectations

2026-04-21 (ET)

2026-04-21

07:20:00

BioAge Labs Reports Significant Results from BGE-102 Clinical Trial

News

9.0

06-30Newsfilter

BioArctic and Eisai to Present New Evidence on Lecanemab at AAIC Conference

7.5

06-22Newsfilter

BioArctic Enters Collaboration Agreement with Eli Lilly

8.5

05-30Newsfilter

BioArctic AB Issues Stock Information

8.5

05-30Newsfilter

BioArctic AB Issues 5,000 Class B Shares for Stock Option Program

5.0

05-28Newsfilter

BioArctic AB Annual General Meeting Resolutions

5.0

05-28Newsfilter

BioArctic AB Annual General Meeting Resolutions

4 Analyst Rating

Wall Street analysts forecast BIOA stock price to rise

2 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

15.00

Averages

37.00

High

73.00

Current: 0.000

Low

15.00

Averages

37.00

High

73.00

Roth Capital

Adam Walsh

Buy

initiated

$36

AI Analysis

2026-05-27

Reason

Roth Capital

Adam Walsh

Price Target

$36

AI Analysis

2026-05-27

initiated

Buy

Reason

Roth Capital analyst Adam Walsh initiated coverage of BioAge Labs with a Buy rating and $36 price target. The firm believes the company's lead asset BGE-102, am NLRP3 program for retinal disease and cardiovascular risk, has blockbuster potential in both indications. BGE-102 produced "class-leading" Phase 1 high-sensitivity C-reactive protein suppression, supporting potential positive Phase 2a cardiovascular risk data, the analyst tells investors in a research note.

BTIG

Buy

initiated

$40

2026-05-13

Reason

BTIG

Price Target

$40

2026-05-13

initiated

Buy

Reason

BTIG initiated coverage of BioAge Labs with a Buy rating and $40 price target. BioAge is a clinical-stage biopharmaceutical company focused on treating disease related to human aging, the analyst tells investors in a research note. The firm says the company mines human datasets to identify proteins and genetic elements whose trajectories in early adulthood predict lifelong outcomes. It has a four-year cash runway with catalysts for BGE-102 in the second half of 2026 and for BGE-105 in mid-2027, BTIG notes. The firm believes BioAge's lead program in cardiovascular risk "seems biologically de-risked" based on readouts linking reductions in systemic inflammation to improved outcomes.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BIOA

Unlock Now

Valuation Metrics

The current forward P/E ratio for BIOAGE Labs Inc (BIOA.O) is 0.00, compared to its 5-year average forward P/E of -2.98. For a more detailed relative valuation and DCF analysis to assess BIOAGE Labs Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.98

Current PE

0.00

Overvalued PE

-0.95

Undervalued PE

-5.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.77

Current EV/EBITDA

-2.67

Overvalued EV/EBITDA

2.12

Undervalued EV/EBITDA

-3.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

34.91

Current PS

31.17

Overvalued PS

59.80

Undervalued PS

10.03

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

next bullish stock

Intellectia · 1062 candidates

Market Cap: >= 500.00MMoving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 55Monthly Average Dollar Volume: >= 200,000

Ticker

Name

Market Cap$

Bank of New York Mellon Corp

82.42B

ZEUS

Olympic Steel Inc

574.91M

SMFG

Sumitomo Mitsui Financial Group Inc

133.35B

BCS

Barclays PLC

89.27B

CUBI

Customers Bancorp Inc

2.74B

TKR

Timken Co

6.54B

Whales Holding BIOA

Sofinnova Investments, Inc.

Cormorant Asset Management, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is BIOAGE Labs Inc (BIOA) stock price today?

The current price of BIOA is 24.4 USD — it has decreased -1.77

What is BIOAGE Labs Inc (BIOA)'s business?

What is the price predicton of BIOA Stock?

Wall Street analysts forecast BIOA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOA is37.00 USD with a low forecast of 15.00 USD and a high forecast of 73.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.